tbuckley/cabot-search huggingface dataset:
Primary payer status and outcomes after autologous hematopoietic stem cell transplant: A national perspective.
Authors: Abu Ahmed Zahidur Rahman, Nusrat Mujib, Marjan Mujib, Tariq Nazir
Journal: Journal of Clinical Oncology (2013)

7042 Background: With healthcare cost in rise, it is of interest to explore variation in healthcare delivery outcome with different payment source. This study was aimed to analyze relationship between payment source and outcome following autologous hematopoietic stem cell transplant (AutoHSCT) in a national database. Methods: We identified all hospitalizations with AutoHSCT (n=1,673) from Nationwide Inpatient Sample (NIS), Healthcare Cost and Utilization Project (HCUP), Agency for Healthcare Research and Quality 2010 database using the ICD 9 procedure codes 41.04 and 41.07. Based on sample weights an estimated 8,444 AutoHSCT procedures were performed nationwide in 2010. Patients were stratified on the basis of payer status: Medicare (27%), Medicaid (12%), private insurance (60%), and uninsured (0.8%). Multivariable logistic regression models were used to determine the association of primary payer status and outcomes. Results: Patients had a mean age of 54 (±13) years, 39% were women and 69% were whites. In-hospital mortality occurred in 1.1%, 2.9% and 3.3% of AutoHSCT patients with primary payer status of private insurance, Medicaid and Medicare respectively. AutoHSCT patients with primary payer status of Medicaid and Medicare had a statistically significant higher chance of in-hospital mortality compared to patients with private insurance (adjusted odds ratios and 95% confidence intervals, 2.68; 1.54-4.65; P &lt;0.001 and 1.90; 1.21-2.99; P=0.005 respectively). Length of stay was longer for Medicare patients (20 ± 11 days) and Medicaid patients (20 ± 12 days) compared to private insurance (18 ± 8 days; P &lt;0.001). Medicare and Medicaid patients also accrued higher hospital charges (USD 175,221 and USD 166,453), compared to private insurance patients (USD 157,120; P &lt;0.001). Conclusions: In this national study Medicaid and Medicare patients had an independent risk for in-hospital mortality compared to private insurance patients. Medicaid and Medicare patients also had longer length of hospital stays and accrued higher hospital charges. This may mandate a closer look into the current resource utilization strategies to reduce such disparities among patients undergoing AutoHSCT.
RECLASSIFICATION OF HOSPITAL PERFORMANCE USING THE EXCESS DAYS IN ACUTE CARE MEASURE VS. 30-DAY READMISSIONS FOR HEART FAILURE AND ACUTE MYOCARDIAL INFARCTION: IMPLICATIONS FOR THE HOSPITAL READMISSIONS REDUCTION PROGRAM
Authors: Rishi Wadhera, Karen E. Joynt Maddox, Nihar R. Desai, Muthiah Vaduganathan, Lauren Gray Gilstrap, Changyu Shen, Robert W. Yeh
Journal: Journal of the American College of Cardiology (2020)
Abstract 16083: Prevalence of E-Cigarette Use Among US Adolescents: Youth Behavioral Risk Factor Survey (YBRFS) 2017
Authors: Hassan Mirbolouk, Sina Kianoush, Michael J Blaha, SM Iftekhar Uddin, Omar Dzaye, Olusola Orimoloye, Mahmoud S Al Rifai, Zeina Dardari, Omar El-Shahaway, Khurram Nasir, Albert D Osei
Journal: Circulation (2019)

Background: E-cigarettes delivers nicotine by heating a liquid derived from tobacco. The prevalence of e-cigarette use and is not well documented among US high schoolers. Aim: Description of e-ciga...
ASSOCIATION OF INTRAPULMONARY VASCULAR DILATATIONS IN LIVER TRANSPLANT CANDIDATES WITH POST-TRANSPLANT MORTALITY
Authors: Lowell Safren, Martin McNamara, Jenna Bekeny, Jim Huang, Rohit Satoskar, Carolina I. Valdiviezo Schlomp, Lorenzo De Marchi, Monvadi Srichai-Parsia
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION OF PLASMA DEHYDROEPIANDROSTERONE SULFATE (DHEA-S) WITH INCIDENT HEART FAILURE IN OLDER MEN AND WOMEN
Authors: Xiaoming Jia, Wensheng Sun, Ron Hoogeveen, Vijay Nambi, Salim Virani, Dennis T. Villareal, George Taffet, Bing Yu, Jan Bressler, Eric Boerwinkle, B. Gwen Windham, James de Lemos, Kunihiro Matsushita, Elizabeth Selvin, Erin Michos, Christie M. Ballantyne
Journal: Journal of the American College of Cardiology (2020)
Patterns of genomic instability differentiate clinical outcomes in patients with invasive breast cancer
Authors: R. E. Ellsworth, T. E. Becker, D. L. Ellsworth, B. Love, J. A. Hooke, C. D. Shriver
Journal: Journal of Clinical Oncology (2006)

10018 Background: Despite improved survival rates for women with breast cancer mainly from improved screening, aggressive therapies may result in the over treatment of many with undesirable physical and economic costs. Identification of molecular profiles in breast tumors that differentiate patients with poor prognosis from those with favorable outcomes would allow for development of effective, individualized treatment regimens with less overall morbidity. Methods: DNA was extracted from primary breast tumors representing stage I (n=75), stage II (n=42), stage III (n=24), and stage IV (n=9) after laser microdissection to isolate pure tumor cell populations. Genomic instability was detected using 52 microsatellite markers representing 26 chromosomal regions frequently altered in breast cancer. Statistical analyses were performed using Fisher’s exact tests and Student t-tests. Results: Patients with poor prognosis (15% of sample population) were defined as those dead of disease (DOD) or alive with disease (AWD), either metastatic disease or disease recurrence; all others had no evidence of disease (NED). Overall levels of genomic instability were significantly higher in tumors from patients with poor prognosis (P&lt;0.0005). At the chromosomal level, chromosome 17p13.3 (P&lt;0.001), 3p13 (P&lt;0.05), and 13q14 (P&lt;0.05) were altered significantly more frequently in patients with poor prognosis compared to NED patients. Conclusions: Chromosomes 3p13, 13q14, and 17p13.3 harbor the fragile histadine triad (FHIT), retinoblastoma 1 (RB1), and hypermethylated in cancer 1 (HIC1) genes, respectively. Alteration of the FHIT gene may promote overall genomic instability while alterations in RB1 and HIC1 has been associated with poor prognosis in patients with breast cancer. Assessment of genomic instability at these three regions may prove useful for stratifying patients by tumor aggressiveness, thus allowing more effective, customized treatment options to be developed. No significant financial relationships to disclose.
Hepatic Regulator of G Protein Signaling 5 Ameliorates Nonalcoholic Fatty Liver Disease by Suppressing Transforming Growth Factor Beta–Activated Kinase 1–c‐Jun‐N‐Terminal Kinase/p38 Signaling
Authors: Junyong Wang, Junpeng Ma, Hongyu Nie, Xiao‐Jing Zhang, Peng Zhang, Zhi‐Gang She, Hongliang Li, Yan‐Xiao Ji, Jingjing Cai
Journal: Hepatology (2020)

Background and Aims Nonalcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver disease, which has no specific pharmacological treatments partially because of the unclear pathophysiological mechanisms. Regulator of G protein signaling (RGSs) proteins are proteins that negatively regulate G protein–coupled receptor (GPCR) signaling. The members of the R4/B subfamily are the smallest RGS proteins in size, and RGS5 belongs to this family, which mediates pluripotent biological functions through canonical G protein–mediated pathways and non‐GPCR pathways. This study combined a genetically engineered rodent model and a transcriptomics‐sequencing approach to investigate the role and regulatory mechanism of RGS5 in the development of NAFLD. Approach and Results This study found that RGS5 protects against NAFLD and nonalcoholic steatohepatitis. Using RNA sequencing and an unbiased systematic investigative approach, this study found that the activation of mitogen‐activated protein kinase signaling cascades in response to metabolic challenge is negatively associated with hepatic RGS5 expression. Mechanistically, we found that the 64‐181 amino‐acid‐sequence (aa) fragment of RGS5 directly interacts with transforming growth factor beta–activated kinase 1 (TAK1) through the 1‐300aa fragment and inhibits TAK1 phosphorylation and the subsequent c‐Jun‐N‐terminal kinase (JNK)/p38 pathway activation. Conclusions In hepatocytes, RGS5 is an essential molecule that protects against the progression of NAFLD. RGS5 directly binds to TAK1, preventing its hyperphosphorylation and the activation of the downstream JNK/p38 signaling cascade. RGS5 is a promising target molecule for fine‐tuning the activity of TAK1 and for the treatment of NAFLD.
Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation
Authors: Johan G. Schnitzler, Renate M. Hoogeveen, Lubna Ali, Koen H.M. Prange, Farahnaz Waissi, Michel van Weeghel, Julian C. Bachmann, Miranda Versloot, Matthew J. Borrelli, Calvin Yeang, Dominique P.V. De Kleijn, Riekelt H. Houtkooper, Marlys L. Koschinsky, Menno P.J. de Winther, Albert K. Groen, Joseph L. Witztum, Sotirios Tsimikas, Erik S.G. Stroes, Jeffrey Kroon
Journal: Circulation Research (2020)

Patients with elevated levels of lipoprotein(a) [Lp(a)] are hallmarked by increased metabolic activity in the arterial wall on positron emission tomography/computed tomography, indicative of a proinflammatory state.We hypothesized that Lp(a) induces endothelial cell inflammation by rewiring endothelial metabolism.We evaluated the impact of Lp(a) on the endothelium and describe that Lp(a), through its oxidized phospholipid content, activates arterial endothelial cells, facilitating increased transendothelial migration of monocytes. Transcriptome analysis of Lp(a)-stimulated human arterial endothelial cells revealed upregulation of inflammatory pathways comprising monocyte adhesion and migration, coinciding with increased 6-phophofructo-2-kinase/fructose-2,6-biphosphatase (PFKFB)-3-mediated glycolysis. ICAM (intercellular adhesion molecule)-1 and PFKFB3 were also found to be upregulated in carotid plaques of patients with elevated levels of Lp(a). Inhibition of PFKFB3 abolished the inflammatory signature with concomitant attenuation of transendothelial migration.Collectively, our findings show that Lp(a) activates the endothelium by enhancing PFKFB3-mediated glycolysis, leading to a proadhesive state, which can be reversed by inhibition of glycolysis. These findings pave the way for therapeutic agents targeting metabolism aimed at reducing inflammation in patients with cardiovascular disease.
INDIVIDUALS WITH CORONARY ARTERY CALCIUM &gt;90TH PERCENTILE MAY BENEFIT FROM MORE AGGRESSIVE PHARMACOLOGICAL MANAGEMENT
Authors: Gowtham Grandhi, Olufunmilayo H. Obisesan, Dzaye Omar, Zeina Dardari, Alan Rozanski, John A. Rumberger, Ron Blankstein, Leslee J. Shaw, Daniel S. Berman, Michael Miedema, Matthew J. Budoff, Khurram Nasir, Michael Blaha, Miguel Cainzos-Achirica
Journal: Journal of the American College of Cardiology (2020)
Surgical staging of uterine cancer: Randomized phase III trial of laparoscopy vs laparotomy—A Gynecologic Oncology Group Study (GOG): Preliminary results
Authors: J. L. Walker, M. Piedmonte, N. Spirtos, S. Eisenkop, J. Schlaerth, R. S. Mannel, G. Spiegel
Journal: Journal of Clinical Oncology (2006)

5010 Background: Feasibility of laparoscopy has been demonstrated, but the toxicity, staging, and survival has not been adequately compared to the traditional open approach. A randomized Phase III trial of 2616 patients was conducted by the GOG from 5/1996 to 9/2005. QOL and complications of surgery were previously reported at SGO. FIGO pathologic staging is the basis of this report. Methods: Clinical Stage I-IIA uterine cancer were eligible, consenting to either technique. The randomization procedures yielded two on laparoscopy arm for every one on the laparotomy arm. Scope participants were required to undergo laparotomy if the complete surgical staging was not feasible, or for resection of cancer. The staging results include: FIGO surgical stage, peritoneal cytology, number of nodes per site, and percent positive nodes at each location: right pelvic, left pelvic, right para-aortic, left para-aortic. Results: 2616 were randomized, 403 were excluded for this analysis: 84 ineligible, 76 sarcoma, 198 incomplete data, 45 were stage IV, leaving 2213 evaluable for lymph node staging of endometrial carcinoma (781 open:1432 scope). Conversion to laparotomy from laparoscopy occurred in 23.7%. Positive or suspicious cytology was found in 5.6% of laparotomy and 7.8% of laparoscopy participants (p = 0.055 n.s.). Pelvic nodes were documented (R 98.8% vs 98.9%, L 98.5% vs 98.1% n.s.) and positive pelvics (any positive 8.8% vs 8.7%; R 5.5% vs 5.8%; L 6.9% vs 6.1% n.s.) were similar. Laparoscopic surgical staging cases were less likely to have para-aortic nodes sampled (L 91.3% vs 85.0% p &lt; 0.001; R 96.0% vs 92.5% P = 0.001), but positve nodes were no different (any positive PA 5.0% vs 4.5%; R 4.1%, 3.4%; L 2.3%, 2.7% n.s.). Final FIGO Staging results (III A: 5.5% vs 5.7% n.s.&amp; IIIC: 9.3% vs 9.5% n.s.) were the same by randomization arm. Conclusion: These results demonstrate that laparoscopic surgical staging of endometrial cancer can be completed in 76.3%. No difference in postive cytology, node positivity rate, or FIGO stage could be attributed to the laparoscopic approach. Conversion to laparotomy is advised when incomplete staging results would yield inadequate information for treatment planning. NCI Funding: UO1CA65221, CA 27469. No significant financial relationships to disclose.
TRENDS IN INCIDENCE, RISK FACTORS AND OUTCOMES OF HEART FAILURE PATIENTS HOSPITALIZED FOR HYPERTENSIVE EMERGENCY FROM A NATIONAL ANALYSIS IN THE UNITED STATES: 2005–2014
Authors: Omar Chehab, Amjad Kanj, Rami Z. Morsi, Rayan Jo Rachwan, Mohit Pahuja, Aiden Abidov
Journal: Journal of the American College of Cardiology (2020)
METABOLIC SYNDROME AND AUTOMATED EPICARDIAL ADIPOSE TISSUE MEASURES PREDICT LONG-TERM RISK OF CARDIAC EVENTS IN ASYMPTOMATIC SUBJECTS
Authors: Andrew Lin, Nathan D. Wong, Frederic Commandeur, Sebastien Cadet, Heidi Gransar, Xi Chen, Stephanie Cantu, Robert Miller, Priscilla McElhinney, Nitesh Nerlekar, Piotr Slomka, Alan Rozanski, Balaji Tamarappoo, Daniel S. Berman, Damini Dey
Journal: Journal of the American College of Cardiology (2020)
DIAGNOSTIC COMPLEXITIES OF LEFT ATRIAL MASSES AND THE VALUE OF A PULMONARY EMBOLISM RESPONSE TEAM
Authors: Lucas Chan, Stephen Morris, Jeremiah F. Haines, Sorcha Allen, Katerina Porcaro, Ibrahim Chowdhury, Ahmad S. Manshad, Alexandru Marginean, Shannon Kuhrau, Dalila Masic, Yevgeniy Brailovsky, Jawed Fareed, Syed Ali, Amir Darki
Journal: Journal of the American College of Cardiology (2020)
GENOTYPIC AND PHENOTYPIC EXPRESSION OF IL2G/T AND IL-8 HELP PREDICT ESTABLISHMENT OF CLINICAL RHEUMATIC HEART DISEASE: DATA FROM THE PROVAR STUDY
Authors: Julia A. Santos, Bruno Ramos Nascimento, Maria Carmo Nunes, Camilo Brandão-de-Resende, Andrea Z. Beaton, Antonio L. Ribeiro, Kaciane K.B. Oliveira, Juliane Franco, Clara L. Fraga, Waydder Antônio A. Costa, Frederico V.B. Macedo, Domingos Sávio G. Ferreira Filho, Craig A. Sable, Walderez O. Dutra
Journal: Journal of the American College of Cardiology (2020)
Trial proactive: A prospective, randomized, multicenter, open label phase III study of active specific immunotherapy with racotumomab plus best support treatment versus best support treatment in patients with advanced non-small cell lung cancer.
Authors: Roberto E Gomez, Amparo Macias, Tania Crombet, Ana Maria Vazquez, Rolando Perez, Maria Laura Ardigo, Agustin Lage
Journal: Journal of Clinical Oncology (2013)

TPS3123 Background: Gangliosides, especially NeuGc-GM3, are attractive targets for cancer immunotherapy. They are not expressed in normal human cells but are overexpressed and involved in tumor growth in several tumors (melanoma, neuroectodermal pediatric tumors and breast cancer). More than 70% of non-small cell lung cancers (NSCLC) express NeuGc-GM3. Racotumomab is an anti-idiotypic monoclonal antibody that mimics NeuGc gangliosides. Administered as a therapeutic vaccine it acts as an antigen, inducing a cellular and humoral immune response against NeuGc-GM3 and other gangliosides. Previous trials have shown its low toxicity and high immunogenicity. Recently, a multicenter, randomized, placebo controlled, double-blind trial in 176 NSCLC (IIIB and IV) patients with at least stable disease after first line therapy and progression free at inclusion showed a statistical significant survival benefit in favor of racotumomab. Methods: This phase III, multinational, randomized (1:1), open label trial will evaluate efficacy and safety of racotumomab plus best supportive care (BSC) versus BSC. 1,082 patients with NSCLC (stages III or IV) showing response or stable disease after standard first-line therapy (platinum-based chemotherapy and radiotherapy) are eligible if they remain free of progression and have a PS ≤ 1. Vaccination consists of an induction period (5 doses, 1 every 14 days) followed by a maintenance period (1 dose every 28 days, until worsening of the PS or unacceptable toxicity occur). Upon progression other onco-specific therapies may be used and vaccination can continue. Overall survival (OS) will be compared using a two-sided log rank test at a significance level (alpha) of 0.05 with 90% power to detect a hazard ratio of 0.79. There will be 3 interim analyses and a final analysis when 758 deaths occur. So far 190 patients have been randomized. An Independent Data Monitoring Committee oversees the study and has so far (last meeting September 2012) concluded that the trial can continue. The trial is registered in ClinicalTrials.gov under NCT01460472. Clinical trial information: NCT01460472.
SINGLE ORAL DOSE ANTI-ARRHYTHMIC DRUGS FOR CARDIOVERSION OF RECENT-ONSET ATRIAL FIBRILLATION EPISODES: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Authors: Omar A. Ibrahim, Emilie P. Belley-Côté, Kevin Um, Adrian Baranchuk, Alexander P. Benz, Shreyash Dalmia, Chang N. Wang, Bishoy Deif, Waleed Alhazzani, Richard Whitlock, Jeff S. Healey, William F. McIntyre
Journal: Journal of the American College of Cardiology (2020)
THE USE OF SHOCKWAVE IN VESSELS PREVIOUSLY TREATED WITH DIRECTIONAL ATHERECTOMY DRUG-COATED BALLOON
Authors: Jared Christensen, Amr Idris, Mohanad Hamandi, Chadi Dib, Karim Al-Azizi, Srinivasa Potluri, Sameh Sayfo
Journal: Journal of the American College of Cardiology (2020)
No reduction in stillbirths, deaths, and injuries in babies for three years, finds review
Authors: Lynn Eaton
Journal: BMJ (2020)

The rate of stillbirths, brain injury, and avoidable deaths in babies in the UK has not changed in three years, findings from the Royal College of Obstetricians and Gynaecologists (RCOG) show.

The president of the college, Edward Morris, has urged maternity units across the UK to learn from the latest report and act on its recommendations. “We owe it to each and every person affected to find out why these deaths and harms occur in order to prevent future cases where possible,” he said.

The Each Baby Counts programme was launched by the RCOG in 2014 to try to reduce the number of babies who die or are left severely disabled as a result of incidents that happen during term labour.

This third annual Each Baby Counts survey1 looked at local investigations of …
Effect of anti-β1 integrin antibody on lung seeding of osteosarcoma cells in live mice visualized by single-cell in vivo imaging.
Authors: Hiroaki Kimura, Yasunori Tome, Masashi Momiyama, Katsuhiro Hayashi, Michael Bouvet, Hiroyuki Tsuchiya, Robert M. Hoffman
Journal: Journal of Clinical Oncology (2012)

10072 Background: Integrins play a role in tumor growth and metastasis (Int. J. Cancer 129, 2905-2915, 2011). However, the effect of integrin inhibition has not been visualized on single cancer cells in vivo. In this study, we used a powerful subcellular in vivo imaging model to demonstrate how an anti-integrin antibody affects seeding and growth of osteosarcoma cells on the lung. Methods: The 143B human osteosarcoma cell line expressing red fluorescent protein (RFP) in the cytoplasm and green fluorescent protein (GFP) in the nucleus was established. Using the double-labeled osteosarcoma cells, single cancer-cell seeding in the lung after i.v. injection of osteosarcoma cells was imaged in live mice. Results: The anti-b1 integrin monoclonal antibody, AIIB2, greatly inhibited the seeding of cancer cells on the lung while a control antibody had no effect. To image the efficacy of the anti-integrin antibody on spontaneous metastasis, mice with orthotopically-growing 143B-RFP cells in the tibia were also treated with AIIB2 or control anti-rat IgG1 antibody. After 3 weeks treatment, mice were sacrificed and primary tumors and lung metastases were evaluated with fluorescence imaging. AIIB2 significantly inhibited spontaneous lung metastasis but not primary tumor growth. In a separate experiment, the anti-β1 integrin antibody increased survival in the orthothopic osteosarcoma model. Conclusions: The efficacy of the anti-β1 integrin antibody against metastasis may be due to inhibition of lung seeding of the cancer cells. The increased survival of mice with orthotopically-growing 143B-RFP treated with AIIB2 may be due to inhibition of metastasis, which in turn may be inhibited by effect of the anti-β1 integrin on cancer-cell seeding in the lung.
A randomized study on lipiodal ethanol mixture (LEM) versus transarterial chemoembolization (TACE) for treatment of hepatocellular carcinoma (HCC): Report of a preplanned interim analysis.
Authors: Stephen Lam Chan, Joyce Hui, Winnie Yeo, Edwin P. Hui, Frankie Mo, Brigette Ma, Anthony T. C. Chan, Simon Yu
Journal: Journal of Clinical Oncology (2012)

e14528 Background: Transarterial injection of LEM produces long-lasting embolization of both arteriolar feeders and peribiliary plexus of HCC leading to infarction of tumor. Our group previously reported the efficacy and safety of LEM for HCC in a phase II clinical trial (Yu et al. J Vasc Interv Radiol. 2008). We initiated a randomized study to compare LEM vs. TACE in HCC. (NCT00467974). Methods: Major eligibility criteria: histologically confirmed HCC; unresectable disease without distant metastases; size ≤15cm; absence of portal vein thrombosis. Consented patients (Pts) were randomized into LEM vs. TACE stratified by tumor size and number. Pts were prospectively followed up and assessed with computed tomography (CT) every 8 weeks. The primary endpoint is overall survival (OS) and secondary endpoints include progression free survival (PFS), RECIST response rate (RR) and toxicity. An interim analysis is planned after recruitment of 70 pts. Results: From 07 to 10, total 70 pts were enrolled. 2 pts withdrew consent and were excluded from the analysis. There were no differences in baseline characteristics between LEM and TACE. Male:Female=53:15; Mean Age=64; Tumor size≤7: &gt;7cm=45:23; Child A:B=55:13. The median follow-up was 2.3 years. The OS of LEM was 25.32 months(m) vs. TACE 22.56m (p=0.38). PFS of LEM was 9.00m vs. TACE 7.8m (p=0.50). Partial response of LEM vs. TACE was 30% vs. 18% (p=0.52); disease control rate of LEM vs. TACE was 80% vs. 70% (p=0.39). Commonest G3 or above toxicities include ALT elevation (LEM 22.2% vs. TACE 9.4%); hyperbilirubinemia (LEM 19.4% vs. 9.4%); pain (LEM 0% vs. TACE 4%). Except pain, there were no differences of toxicities between LEM and TACE after procedure (p=0.04). Conclusions: At interim analysis, LEM showed comparable efficacy and toxicity profile to TACE. A trend of better OS, PFS and RR was observed in LEM arm but statistically insignificant. Further accrual and follow-up is ongoing.